





INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 15/12, C07K 14/47, 16/18, C12Q 1/68		A2	(11) International Publication Number: WO 00/03013
			(43) International Publication Date: 20 January 2000 (20.01.00)
(21) International Application Number: PCT/EP99/04938		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 12 July 1999 (12.07.99)		Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(30) Priority Data: 98202336.8 10 July 1998 (10.07.98) EP			
(71) Applicant (for all designated States except US): AMS-TERDAM MOLECULAR THERAPEUTICS [NL/NL]; Bernadottelaan 15, NL-3527 GA Utrecht (NL).			
(72) Inventors; and (75) Inventors/Applicants (for US only): CHAMULEAU, Robert, Antoine, François, Marie [NL/NL]; Van Ostadelaan 76, NL-1412 JL Naarden (NL). GROENINK, Martijn [NL/NL]; Torasistraat 5, NL-1019 RT Amsterdam (NL). VAN DER VLIET, Hendrik, Niels [NL/NL]; Bovenweg 18, NL-1276 XZ Huizen (NL). LEEGWATER, Adam, Cornelis, Jozef [NL/NL]; f Modderweidje 9, NL-1738 CR Waarland (NL).			
(74) Agent: VAN SOMEREN, Petronella, Francisca, Hendrika, Maria; Arnold & Siedsma, Sweelinckplein 1, NL-2517 GK The Hague (NL).			

(54) Title: GENE AND PROTEIN INVOLVED IN LIVER REGENERATION

(57) Abstract

The present invention relates to a gene involved in regeneration processes of the liver and comprising a nucleotide sequence which is at least 70 % homologous to the sequence of figure 1 or the sequence of figure 6, or the complementary strand thereof, for use in the design of PCR probes for detecting nucleotide sequences in a source material, which nucleotide sequences represent genes corresponding with the gene sequence of figure 1 or the sequence of figure 6; protein encoded by said gene for use in diagnosis of liver regeneration and/or liver cell proliferation; and antibodies directed against this protein, a PCR primer comprising at least part of said gene as a probe, a single stranded nucleotide sequence being at least in part complementary to the messenger RNA transcribed from said gene as a probe an expression vector and a host cell comprising said nucleotide sequence, for use in a method for detecting the occurrence of liver cell proliferation in a subject.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

GENE AND PROTEIN INVOLVED IN LIVER REGENERATION

The present invention relates to the detection of a novel gene and protein involved in liver cell proliferation. The gene and protein and related molecules, such as nucleotide probes derived from the gene and antibodies directed to the protein form also part of the invention. The gene will be identified herein as RAP3 gene. The corresponding protein is called RAP3 protein.

The adult liver has the capacity to regenerate after damage or partial resection. This process may allow for recovery from hepatic injuries caused by viruses, toxins, ischemia, surgery, and auxiliary liver transplantation. Liver regeneration has been studied extensively in the rat after a 70% partial hepatectomy. During the first four hours following partial hepatectomy there is a rapid, transient transcriptional activation of genes involved in the immediate early response. After induction of these immediate early genes during the transition from the quiescent state of the liver (G_0) to the growth phase (G_1), a delayed early gene activation is initiated which peaks during the transition of the G_1 to the DNA synthesis phase (S phase).

In the research that led to the present invention novel genes involved in the delayed early response were identified by analyzing gene expression in rat liver at six hours after 70% partial hepatectomy. Upregulated genes were selected by cDNA subtractive hybridization. Upregulation was quantified by Northern blotting and the truly upregulated genes were characterized by sequence analysis.

Twelve genes were found to be upregulated at different degrees (1.5 to 10.4 fold) six hours after partial hepatectomy. Sequence analysis revealed that eight of the upregulated genes have previously been reported to be associated with liver regeneration or cell proliferation in general, one has previously been assigned an unrelated function and three have no sequence similarity to known genes.

The various upregulated genes showed two distinct gene expression patterns during a 30 hour period after partial hepatectomy. The first pattern has two peaks coincident with the G₁ phases of two consecutive hepatic cell cycles. The second one shows a narrow peak at six hours after which the gene is downregulated. The novel RAP3 gene (RAP: regeneration associated protein) which was most upregulated (3.3 fold), showed the latter gene expression pattern.

10 The full length cDNA of this gene was isolated from a rat liver cDNA library. Sequence analysis showed two full length cDNAs of 1282 and 1834 bp, respectively, encoding a novel protein of 367 amino acid residues. Figures 1A and 1B show the nucleotide sequence of the
15 cDNA's. Figure 2 shows the derived amino acid sequence.

In addition, the cDNA of the human RAP3 gene was isolated. Sequence analysis showed two cDNAs of 1282 and 1867 bp respectively, encoding a protein of 363 amino acids. Figures 6A and 6B show the nucleotide sequence of
20 the cDNA's. Figure 7 shows the derived amino acid sequence. The 1867 human RAP3 cDNA shows a 76% homology with the 1834 rat RAP3 cDNA.

On the basis of this finding it became possible to design probes, primers and reagents for use in
25 diagnosis. Probes and primers are generally based on the nucleotide sequence of the genes. Hybridization probes can comprise the whole or a large part of the coding or complementary strand of the sequence. PCR primers are typically smaller and encompass
30 about between 10 and 50, preferably between 15 and 30, more preferably about 20 nucleotides.

The nucleotide sequences of some suitable PCR primers are given in the following table.

35 Table I

primer name	nucleotide sequence
F1RAP	5' GCA TCG TGG AAA GCA TGG CT 3'
F215RAP	5' GGG ACC CTT GAG AGA GCC TG 3'

F371RAP	5' CTT GAG GCA GCA GTT GAA AC 3'
F571RAP	5' TCC ACC CTT ATG CAG AAC GC 3'
F771RAP	5' AGT ACC TTC ATC CGT GTC AG 3'
F971RAP	5' CGC CTT CGC TCC AGA GTT GG 3'
5 F1171RAP	5' AGG GTG GAG GGT CCT GCA TA 3'
F1371RAP	5' GCA AGC CAG TAC TTG ACC GT 3'
F1621RAP	5' GTG GTC CTG CTG GGG GAT CA 3'
R234RAP	5' CAG GCT CTC TCA AGG GTC CC 3'
R420RAP	5' CTA CCT GCT CCA TCA GCT CG 3'
10 R570RAP	5' AGA GTT CTT TGA CTC GGT CC 3'
R770RAP	5' GAG CTC ATC TCG CAG CTG AT 3'
R970RAP	5' CTG TGG CTA GGC GGG GGT GG 3'
R1170RAP	5' CTG CCT ATT AGG CCA TGC TG 3'
R1370RAP	5' AGT CAG TCT CCC CCG CAC AC 3'
15 R1570RAP	5' TGG CAG GGA TGT ACA CAC TC 3'
R1837RAP	5' TTT CCA TCA TGA GCG TCT AT 3'

The hybridization probes can be labeled with a detectable label, such as a radioactive or biotin label.

20 Diagnosis of expression of the gene can be performed by means of a Northern blot. Total RNA or mRNA of a sample is separated on an agarose gel. The separation pattern is transferred to a nylon or nitrocellulose filter. An increase or decrease in the
25 expression level is subsequently detected by hybridization with the above described hybridization probe. Typically a reference sample is included for comparison.

In case the protein is the basic macromolecule
30 for diagnosis polyclonal or monoclonal antibodies are used for detection. The skilled person is very well capable of preparing such antibodies based on his common knowledge. Antibodies against the protein are part of the present invention.

35 Samples to be diagnosed can be a liver biopsy, plasma or serum. The latter can be used because the protein is secreted in the blood stream.

With the above described diagnostic methods an increase or decrease in the expression of the gene of the invention can be detected. The information that can thus be obtained is useful for establishing the efficacy of
5 therapeutic agents stimulating liver regeneration and for patients who underwent an (auxiliary) liver transplantation and for monitoring patients treated with a bioartificial liver.

The invention is further illustrated in the
10 following examples, which are in no way intended to be limiting to the invention. In the examples reference is made to the following figures:

Figure 1A is the nucleotide sequence of the
1282 bp cDNA.

15 Figure 1B is the nucleotide sequence of the
1834 bp cDNA.

Figure 2 shows the deduced amino acid sequence of the rap3 protein.

Figure 3 shows a polyacrylamide gel of liver
20 cDNA fragments before and after subtraction. 26 cDNA fragments were found to be enriched after subtraction. Some of these are indicated by arrows. Lane 1 shows liver cDNA fragments of 6 hours 70% partial hepatectomy before subtraction. Lane 2 shows cDNA fragments of 6 hours 70%
25 partial hepatectomy after subtraction.

Figure 4 shows the results of the Northern blot analysis of the temporal expression of RAP3 up to 30 hours after 70% partial hepatectomy. Panel A represents the Northern blot mRNA expression patterns at 3, 6, 12,
30 18, 24 and 30 hours after the 70% hepatectomy (hpx) and laparotomy (sham). Panel B represents the quantified hybridization signals indicated in PhosphorImager arbitrary units obtained at 6, 12, 18, 24 and 30 hours after the 70% hepatectomy and laparotomy.

35 The novel gene RAP3 is mostly upregulated 6 hours after partial hepatectomy after which it becomes downregulated.

Figure 5 shows a rat tissue Northern blot hybridized with a RAP3 cDNA probe. The RAP3 gene is specifically expressed in the liver.

Figure 6A shows the nucleotide sequence of the
5 1282 bp human RAP3 cDNA.

Figure 6B shows the nucleotide sequence of the
1867 bp human RAP3 cDNA (B).

Figure 7 shows the deduced amino acid sequence
of the human rap3 protein.

10 Figure 8 shows the results of immunoblotting.
About 6 ng of denatured rat RAP-3 protein was blotted on
each strip. The strips were incubated with two antisera
in various concentrations: 1-3: antiserum against
purified native rat RAP3 protein (concentrations: 1:2000,
15 1:8000, 1:32000); 4-7: antiserum against purified
denatured rat RAP3 protein (1:2000, 1:8000, 1:32000,
1:128000).

Figure 9 shows the results of an immunoblot
after analysis with the program LumiAnalyst. 2.5 µl rat
20 plasma was blotted per lane. The blot was incubated with
antiserum against the denatured RAP3 protein. (hpx:
plasma after 70% partial hepatectomy; sham: plasma after
sham operation; positive control: about 10 ng purified
denatured rat RAP3 protein).

25

EXAMPLES

EXAMPLE 1

Isolation of RAP3 gene associated with liver regeneration

30 **1. Introduction**

Recovery from Hepatic injuries caused by
viruses, toxins, ischemia, surgery and auxiliary liver
transplantation can be achieved by regeneration of the
liver. The regeneration process has been studied
35 extensively in the rat after a 70% partial hepatectomy.

During the first four hours following partial
hepatectomy there is a rapid, transient transcriptional
response. After this induction during the transition from

the quiescent state of the liver (G_0) to the growth phase (G_1), a delayed early gene activation is initiated, which peaks during the transition of the G_1 to the DNA synthesis phase (S phase).

- 5 This example demonstrates the isolation and identification of genes which are upregulated in the regenerating liver 6 hours after 70% partial hepatectomy.

2. Methods

10 2.1 Rat liver tissue preparation

- Experiments were carried out in compliance with the guidelines on the care and use of laboratory animals of the University of Amsterdam. Regenerating liver was obtained from male Wistar rats (200-225 g). Rats were
15 anesthetized with ether and subjected to midventral laparotomy. Subsequently, the left lateral and the median liver lobes were removed (70% partial hepatectomy) (G.M. Higgins and R.M. Anderson, Arch. Pathol. 12, 186 (1931)). For sham-operated animals, the liver was exposed
20 by a midventral laparotomy.

The rats were allowed to recover from anesthesia. At 3, 6, 12, 18, 24, and 30 hours, respectively, after the 70% partial hepatectomy and sham surgery the animals were killed and the remaining liver
25 was immediately harvested.

2.2 RNA isolation

Total liver RNA was isolated from liver tissue using the Trizol reagent kit (Life Technologies). Liver poly A⁺ RNA was isolated from total liver RNA using oligo-
5 (dT)-cellulose (Boehringer Mannheim GmbH) affinity chromatography as described previously (Maniatis, T., Fritsch, E.F., and Sambrook, J. (1982) Molecular cloning: A laboratory Manual, Cold Spring Harbor, NY). To obtain
10 highly pure poly A⁺ RNA populations the oligo-(dT)-cellulose step was performed twice. The integrity of the poly A⁺ RNA populations was determined on Northern blot by hybridization with glutathione-S transferase (data not shown).

15 2.3 PCR-select cDNA subtraction

The PCR-select cDNA subtraction kit (Clontech) was used to selectively amplify delayed early genes differentially expressed during liver regeneration. This method subtracts sequences common to both cDNA
20 populations by suppressing undesirable PCR amplification, rather than by physically separating single stranded and double-stranded DNA. The 6 hours 70% partial hepatectomy liver poly A⁺ population, containing the differentially expressed mRNA's, was compared with the 6 hours
25 laparotomy liver mRNA population. Delayed-early genes start to appear 3 to 4 hours after the 70% partial hepatectomy. By using a laparotomy liver mRNA population rather than a normal liver mRNA population, the two populations were equalized for acute phase mRNA's, which
30 are induced by the operation itself.

The PCR-select cDNA subtraction was performed according to the manufacturer's protocol with the following modifications. After two hybridizations, a nested PCR was used to selectively amplify the
35 differentially expressed sequences. The second, nested PCR was performed in the presence of 0.5 μ M [α -³³P]dATP (1200 Ci/mmol, final volume 25 μ l). Subsequently, the amplified and differentially expressed cDNA fragments

were visualized on a denaturing 4% polyacrylamide DNA sequencing gel. An X-ray film (Biomax, Kodak) was exposed overnight to the unfixed, dried gel.

Figure 3 shows the results of the subtraction.

5 Before subtraction (lane 1), the majority of the cDNA's were poorly identifiable, indicating the presence of many cDNA fragments of different molecular size. After subtraction (lane 2), 26 distinct cDNA fragments were observed as bands that were not apparent before
10 subtraction.

2.4 Isolation and identification of visualized cDNA fragments

The 26 cDNA fragments that became visible after
15 PCR-select cDNA subtraction were excised from the dried polyacrylamide gel and heated to 100°C for 5 minutes. Subsequently, 25 µl of the aqueous cDNA extract was used to amplify the cDNA by PCR with the nested primers used in the PCR-select cDNA subtraction. The PCR product was
20 ligated into pCR II (Invitrogen), transformed into INVαF' competent cells, and plated out on agar plates containing ampicillin and X-Gal. Of each cloned PCR product, 6 white colonies were analyzed by PCR with T7 and SP6 primers for the presence of an insert.

25 Subsequently, plasmids containing an insert were purified using QIAprep (Qiagen) and the sequences of the inserts were determined using a dye terminator cycle sequencing system (Perkin Elmer) and a 377 DNA sequencer (ABI PRISM).

30

2.5 Northern blot analysis

To determine whether the expression of the genes found by the PCR-select subtractive hybridization is truly increased 6 hours after partial hepatectomy,
35 Northern blot analysis was carried out using the purified cDNA fragments as probes. Poly A⁺ RNA samples (0.8 µg) of the liver 6 hours after the hepatectomy and sham operation were electrophoresed on a 0.22 M formaldehyde-

1% agarose gel, and blotted onto a Hybond-N nylon membrane (Amersham) by capillary transfer overnight. For fixation of the poly A⁺ RNA the blots were baked in an oven at 80°C for 2 hours.

- 5 The inserts of the sequenced clones were amplified by PCR using the nested primers of the PCR-select cDNA subtraction method. Qiaquick-spin columns (Qiagen) were used to purify the PCR products. The purified PCR products were radioactively labelled
- 10 according to the hexamer-random primed method following the manufacturer's protocol (Promega), purified on Qiaquick-spin columns (Qiagen), and hybridized with the blots. Prehybridization (2 hours, 42°C) and hybridization (overnight, 42°C) was performed in 5 x SSPE, 50%
- 15 formamide, 5 x Denhardt, 0.5% SDS, and 0.1 mg/ml sheared heat-denatured herring sperm DNA.

- Following hybridization the blots were washed with 2 x SSC and 0.1% SDS for 15 min at room temperature and 42°C, respectively. Subsequently, the solution was
- 20 replaced with 1 x SSC and 0.1% SDS and the blots were washed for 15 min at room temperature and at 42°C, respectively. The amount of hybridization was analyzed and quantified using a PhosphorImager (Molecular Dynamics).

- 25 The fold induction of the mRNA levels observed in the 70% partially hepatectomized animals over the sham operated animals after the specific hybridization was adjusted for variability in RNA loading.

- The genes which were upregulated 1.5 times or
- 30 more 6 hours after 70% hepatectomy together with their identity are given in Table II. Beside these twelve genes, three genes are indicated which expression could not be detected on Northern blot. The expression of the novel RAP3 gene was found to be upregulated 3.3 fold.

Table II

GENES UPREGULATED 6 HOURS AFTER A 70%		
	Identity of gene	Function
5	Fibronectin	Liver regeneration
	An intracisternal-A	Liver regeneration
	γ -Actin	Liver regeneration
	Ribophorin I	Liver regeneration
		5.5, 1.7 & 2.3
10	α_2 -Macroglobulin	Hepatocyte proliferation <u>in vitro</u>
	Ribosomal Protein S5	Cell cycle
	Ribosomal Protein L13	Cell cycle
	Amyloid A Protein	Growth factor
15	Entactin	N.D.*
	TCP-1-Containing	1.5
	Chaperonin related gene	
	31 kDa Putative	N.D.*
20	Serine/ Threonine protein kinase	
	Novel RAP1**	Unknown
	Novel RAP2**	Unknown
	Novel RAP3**	Unknown
25	Novel RAP4**	Unknown

* N.D. = not detectable on Northern blot

** RAP1-3: Regeneration Associated Protein1-3)

30 EXAMPLE 2

Isolation and characterization of the full length RAP3

cDNA

Library screening and sequence analysis

A rat liver cDNA library was prepared from poly
 35 A⁺ RNA isolated from the rat liver 6 hours after 70%
 hepatectomy. To obtain full length cDNA, the Great
 Lengths cDNA Synthesis Kit (Clontech) was used following
 the manufacturer's protocol. The adaptor ligated full

length cDNA inserts were cloned into the mammalian expression vector pCI at the EcoRI restriction site.

After transformation into DH10B electrocompetent cells (Gibco), the cDNA library was
5 plated at a density of about 3,000 plaques per 150-mm-diameter petri dish. Colonies were lifted onto a Hybond-N nylon membrane (Amersham). The lift was hybridized with the ³²P-labeled RAP3 PCR fragment prepared according to the hexamer-random primed method following the
10 manufacturer's protocol (Promega).

Following hybridization, the lift was washed and analyzed using a PhosphorImager (Molecular Dynamics). From the nine positive clones, the plasmid DNA was purified and the sequences of the inserts were determined
15 using a Big dye terminator cycle sequencing system (Perkin Elmer) and an ABI PRISM 377 DNA sequencer (Perkin Elmer). The RAP3 cDNA was obtained by comparing the nine sequences with the sequence of the RAP3 PCR fragment. Two possible clones were detected and the start and end of
20 the cDNA were confirmed by 5'- and 3'-RACE reactions carried out following the protocol of the Marathon cDNA Amplification kit (Clontech).

Based on the nucleotide sequence of the clones, PCR reactions were carried out with cDNA prepared from
25 poly A⁺ RNA of the rat liver 6 hours after 70% hepatectomy. The PCR products comprised the whole RAP3 cDNA, of which the nucleotide sequence was determined by bidirectionally sequencing the PCR products using 20 bp primers based on the already known nucleotide sequence
30 data of the RAP3 cDNA.

Two RAP3 cDNA molecules were detected of 1282 and 1834 bp respectively. The latter showed the same nucleotide sequence as the first, but contained an additional 552 bp nucleotide part at the 3' side.
35 The nucleotide sequence of the 1282 bp RAP3 cDNA is as shown in Figure 1A.

The nucleotide sequence of the 1834 bp RAP3 cDNA is shown in Figure 1B.

Using GCG DNA software the nucleotide sequences were translated into the amino acid sequence. By analyzing the six reading frames, the largest possible protein was chosen as the RAP3 protein. Its amino acid sequence, starting with a methionine residue and ending at a stop codon, was the most likely one to form a protein in comparison with the other smaller possible proteins. Both RAP3 cDNA molecules encode the same RAP3 protein.

10 The amino acid sequence of RAP3 protein as deduced from the nucleotide sequence is shown in Figure 2.

15 **EXAMPLE 3**

Temporal expression between 3 and 30 hours after 70% partial hepatectomy

To define the temporal expression of the RAP3 gene, mRNA levels at 3, 6, 12, 18, 24, and 30 hours after the 70% partial hepatectomy and laparotomy were analyzed by the Northern blot procedure as described in example 1. Total RNA samples (20 µg) of the rat liver isolated at the various time points were electrophoresed. The Northern blot was hybridized with a radioactively labeled probe comprising basepairs 370 to 1834 of the large RAP3 cDNA. The result of the Northern blot and the quantified expression pattern are given in Figure 4. The expression pattern is presented as the hybridization signal in PhosphorImager arbitrary units obtained at 3, 6, 12, 18, 24, and 30 hours after the 70% partial hepatectomy and laparotomy.

Both RAP3 mRNA sizes are mostly upregulated 6 hours after partial hepatectomy after which they become downregulated.

35 The same procedure was carried out with probes of the other upregulated genes obtained by the PCR-select subtraction. Two distinct gene expression patterns during the 30 hour period after partial hepatectomy were found.

The first pattern has two peaks coincident with the G₁ phases of two consecutive hepatic cycles. The second one shows a narrow peak at six hours after which the gene is downregulated, just like the expression pattern of the novel RAP3 gene.

Determination of tissue specific expression

A Northern blot was prepared to determine expression of RAP3 mRNA in different tissues. The various tissues (skeletal muscle, spleen, liver, kidney, heart, lung and brain) were isolated from a female Wistar rat (175 g). The experiment was carried out in compliance with the guidelines on the care and use of laboratory animals of the University of Amsterdam. Total liver RNA was isolated from the tissues using the Trizol reagent kit (Life Technologies). A Northern blot was prepared from 20 µg total RNA samples and Northern blot analysis was carried out as described in example 1. A radioactively labeled probe comprising basepairs 370 to 1834 of the large RAP3 cDNA was used for the hybridization. The resulting Northern blot is given in Figure 5.

The RAP3 mRNA appeared to be clearly expressed in the liver and not at any detectable level in the other examined tissues. Because of this liver specificity and the 3.3 fold upregulation six hours after hepatectomy, the novel gene RAP3 was considered to be important in the process of liver regeneration.

30

EXAMPLE 4

Isolation and characterization of the full length human RAP3 cDNA

The Superscript Human liver cDNA library was purchased from Life Technologies. It contained liver cDNA from a 9-year old caucasian female directionally cloned into the pCMV¹SPORT vector, and transformed into DH12S cells.

The cDNA library was plated at a density of about 25,000 plaques per 150-mm-diameter petri dish. Colonies were lifted onto a Hybond-N nylon membrane (Amersham). The lift was hybridized with a ³²P-labeled RAP3 cDNA fragment, consisting of the overlapping nucleotide sequence of the two rat RAP3 cDNA molecules. The labeling was carried out according to the hexamer random primed method following the manufacturer's protocol (Promega). Following hybridization, the membrane was washed with low stringency and analyzed using a PhosphorImager (Molecular Dynamics).

Eight positive colonies and its near surroundings were cut from the agar plate and each transferred into 1 ml LB medium. 20 µl was plated on new agar plates and the hybridization protocol was repeated. Duplo clones of the eight positive colonies were isolated from the plate. The plasmid DNA was purified and the sequences of the inserts were determined using a Big Dye terminator cycle sequencing system (Perkin Elmer) and an ABI PRISM 377 DNA sequencer (Perkin Elmer). For sequencing initially the T7 and SP6 promotor primers were used and later on primers identical to twenty nucleotides of the sequenced part of the inserts.

By bidirectionally sequencing two human RAP3 cDNA nucleotide sequences were detected, both being presented by four of the eight examined clones. The two RAP3 cDNA molecules were 1322 and 1867 bp respectively. The latter showed the same nucleotide sequence as the first, but contained an additional 545 bp nucleotide part at the 3' side. The 1867 human RAP3 cDNA shows a 76% identity with the 1834 bp rat RAP3 cDNA.

The nucleotide sequence of the 1282 bp human RAP3 cDNA is shown in Figure 6A. The nucleotide sequence of the 1867 bp human RAP3 cDNA is shown in Figure 6B.

Using GCG DNA software the nucleotide sequences were translated into the amino acid sequence. By analyzing the six reading frames, the largest possible protein was chosen as the human RAP3 protein. Its amino

acid sequence, starting with a methionine residue and ending at a stop codon, was the most likely one to form a protein in comparison with the other smaller possible proteins. Both human rRAP3 cDNA molecules encode the same rap3 protein. The human RAP3 protein shows a 73% identity with the rat RAP3 protein, indicating that they indeed are the same protein but only expressed in different species.

The 363 residues counting amino acid sequence of the human RAP3 protein as deduced from the nucleotide sequence is shown in Figure 7.

EXAMPLE 5

15 Production of polyclonal antibodies against both rat and human RAP3

Expression of RAP3 protein

Both the rat and human cDNA sequences encoding the RAP3 protein without its presequence (the first 20 amino acid residues of the protein) were cloned into the pET-15b expression vector (Novagen) at the NdeI restriction site. The inserts were flanked by NdeI restriction sites, which had been introduced by PCR. By cloning at the NdeI site, a His-tag is expressed in front of the RAP3 protein, which is necessary for purification of the protein.

The vectors containing the RAP3 insert were transformed into the bacterial strain BL21(DE3) (Novagen). One colony was inoculated in 200 ml ampicillin containing LB medium. The medium was incubated at 37 °C. After reaching an OD₆₀₀ of 0.6/0.7 the medium was incubated for another four hours after which the cells were isolated.

35 The rat RAP3 protein was purified under non-denaturing conditions from the soluble fraction of the cells and under denaturing conditions from the insoluble fraction (inclusion bodies) of the cells. The human RAP3

protein was only purified under denaturing conditions from the insoluble fraction. The purification was carried out using His•Bind resin and columns (Novagen) following the manufacturer's protocol.

5 For identification the purified proteins were sequenced. Therefore the His-tag was removed from the proteins by cleavage with biotinylated thrombin (Novagen) following the manufacturer's protocol. The proteins were run on a 10% SDS-PAGE gel in Laemmli running buffer. The
10 gel was blotted onto a PVDF membrane in CAPS buffer. The blot was shortly stained with Fast Blue (Pharmacia). The proteins were sequenced from blot by the Protein Research Facility Amsterdam of the E.C. Slater Institute in Amsterdam. The first thirteen amino acid residues of the
15 expressed proteins after the His-tag were identified to be the same as the amino acid residues 21-33 of the rat and human RAP3 proteins as depicted in Figure 2 and 7 respectively. This indicates that the expected RAP3 proteins were expressed and can be used as antigens to
20 raise polyclonal antibodies against the RAP3 proteins.

Immunisation

Rabbits were immunised with the various RAP3 proteins in order to obtain polyclonal antibodies against
25 the rat and human RAP3 protein. About 200 µg purified RAP3 protein (including the His-tag) was suspended in Freund Complete Adjuvant and injected intracutaneously into 15 weeks old New Zealand White rabbits. After 2 months a booster of about 200 µg protein in Freund
30 Incomplete Adjuvant was given intramuscular. One month later a booster of about 200 µg protein in PBS was given intramuscular and one to two weeks hereafter serum was collected from the rabbits.

The serum was tested in various concentrations for its
35 ability to recognize the purified RAP3 protein. The sera against rat RAP3 were tested on the purified denatured rat RAP3 protein by immunoblotting. About 45 ng protein was run on a 10% SDS-PAGE gel in Laemmli running buffer.

The gel was blotted onto a PVDF membrane in Laemmli running buffer containing 20% methanol. The blot was cut into seven strips each loaded with approximately 6 ng rat RAP3 protein. The strips were blocked using Protifar 5 (Nutricia), washed and incubated with antibodies (1 h, 20 °C) according standard methods. The strips were incubated first with the sera against the rat RAP3 protein in various concentrations ranging from 1:2,000 to 1:128,000. Secondly the strips were incubated with alkaline 10 phosphatase labeled goat anti-rabbit immunoglobulins (DAKO). The strips were now incubated with precipitating BM purple AP substrate (Boehringer Mannheim) following the manufacturer's protocol. Reaction of alkaline phosphatase with the substrate leaves a dark purple band. 15 The results are given in Figure 8. As shown a clear band at the right protein size appears even at the lowest concentrations. Serum from the rabbits before immunisations did not react with the RAP3 protein (data not shown). So polyclonal antibodies were obtained 20 against the rat RAP3 protein. In the same way polyclonal antibodies against human RAP3 will be obtained.

EXAMPLE 6

25 Detection of RAP3 protein in rat plasma

Rat plasma isolation

Experiments were carried out in compliance with the guidelines on the care and use of laboratory animals 30 of the University of Amsterdam. Regenerating liver was obtained from male Wistar rats (200-225 g). Rats were anesthetized with Hypnorm and subjected to midventral laparotomy. Subsequently, the left lateral and the median liver lobes were removed (70% partial hepatectomy) {G.M. 35 Higgins and R.M. Anderson, Arch. Pathol. 12, 186 (1931)}. For sham-operated animals, the liver was exposed by a midventral laparotomy. The rats were allowed to recover from anesthesia. At 3, 6, 12 hours, respectively, after

the 70% partial hepatectomy and sham surgery the blood of the animals was heparinized and collected. The plasma of the rats was obtained by 5 minutes centrifugation at 1650g.

5

Immunoblotting

A Western blot was prepared as described before containing 2.5 μ l plasma samples. Plasma samples of 3, 6 and 12 hours after both a sham operation and a 70% partial hepatectomy were examined. The blot was blocked (using Protifar), washed and incubated with antibodies (1 h, 20 °C) according standard methods. The blot was incubated first with serum against the denatured rat RAP3 protein in a 1:6,000 dilution. Secondly the strips were incubated with horse radish peroxidase labeled goat anti-rabbit immunoglobulins (DAKO). The blot was now incubated with Lumi-light^{plus} Western blotting Substrate (Boehringer Mannheim) following the manufacturer's protocol. Analysis with the program LumiAnalyst gave the result as shown in Figure 9. RAP3 was found to be present in the plasma, so the liver excretes RAP3 into the blood. The appearing RAP3 has a somewhat smaller molecular weight than the positive control, because the positive control contains a His-tag in front of the protein. Especially the plasma samples of 6 and 12 hours after the hepatectomy showed an increase in RAP3 protein contents compared to the sham operation. So the concentration of the RAP3 protein is elevated in rat blood after 6 to 12 hours after a 70% hepatectomy.

30

EXAMPLE 7

Detection of changes of the amount of the RAP3 protein in the blood circulation

35

In order to detect changes in the amount of the RAP3 protein in the blood circulation a specific enzyme-linked immunosorbent assay (ELISA) is developed. Specific polyclonal and/or monoclonal antibodies are raised

against the whole protein or a part of the protein. The protein, human or rat, is expressed in a prokaryotic or eukaryotic expression system or part of the protein is synthesized chemically. Monoclonal and polyclonal
5 antibodies, raised in rabbits, are isolated by common techniques as described previously (Coligan, J.E., Kruisbeek, A.M., Margulies, D.M., Shevach, E.M., and Strober, W. (1994) Current Protocols in Immunology, John Wiley & Sons, Inc. Chicester, New York).

CLAIMS

1. Gene involved in regeneration processes of the liver and comprising a nucleotide sequence which is at least 70% homologous to the sequence shown in Fig. 1 or at least 70% homologous to the sequence shown Fig. 6, or the complementary strand thereof.

2. Gene as claimed in claim 1, **characterized in that** its cDNA has a nucleotide sequence which is at least 70% homologous to the nucleotide sequence as depicted in Fig. 1 or at least 70% homologous to the nucleotide sequence as depicted in Fig. 6, or the complementary strand thereof.

3. Gene as claimed in claims 1 or 2 for use in the design of PCR probes for detecting nucleotide sequences in a source material, which nucleotide sequences represent genes corresponding with the gene sequence shown in Fig. 1 or with the gene sequence shown in Fig. 6.

4. Gene as claimed in claims 1 or 2 for use as a marker of liver proliferation.

5. Protein encoded by a gene as defined in claims 1 and 2 and comprising an amino acid sequence which is at least 70% homologous to the amino acid sequence given in Fig. 2 or at least 70% homologous to the amino acid sequence given in Fig. 7.

6. Protein as claimed in claim 5 having the amino acid sequence as depicted in Fig. 2 or Fig. 7.

7. Protein as claimed in claims 5 and 6 for use in diagnosis of liver regeneration and/or liver cell proliferation.

8. Antibodies directed against a protein as claimed in claims 5 and 6.

9. Antibodies as claimed in claim 7 for use in a method for detecting the occurrence of liver cell proliferation in a subject.

10. Antibodies as claimed in claim 8 or 9 which antibodies are monoclonal antibodies.

11. Antibodies as claimed in claim 8 or 9 which antibodies are polyclonal antibodies.

12. PCR primer, comprising at least part of the gene as claimed in claim 1.

13. PCR primer, comprising at least part of the nucleotide sequence as shown in Fig. 1 or at least part of the nucleotide sequence as shown in Fig. 6, or its complementary strand.

14. PCR primer as claimed in claims 12 and 13, wherein the "at least part of the nucleotide sequence" encompasses 10 to 50, preferably 15 to 30, more preferably about 20 nucleotides.

15. PCR primer as claimed in claims 12 to 14 having the nucleotide sequence as depicted in Table I or the complementary strand thereof.

16. PCR primer as claimed in claims 12 to 15 for use as a probe in a method for detecting the occurrence of liver proliferation in a subject.

17. PCR primer as claimed in claims 12 to 15 for use in the detection of gene homologous to the gene as claimed in claims 1 to 3.

18. Single stranded nucleotide sequence being at least in part complementary to the messenger RNA transcribed from a gene as claimed in claims 1 to 3.

19. Single stranded nucleotide sequence as claimed in claim 18 which is antisense RNA.

20. Single stranded nucleotide sequence being at least in part complementary to the DNA or the cDNA from a gene as claimed in claims 1 to 3.

21. Single stranded nucleotide sequence as claimed in claims 18-20, further provided with a detectable label.

22. Nucleotide sequence as claimed in claims 18 to 21 for use as a probe in a method for detecting the occurrence of liver proliferation in a subject.

23. Nucleotide sequence as claimed in claim 22, **characterized in that** the method in which the nucleotide sequence is used as a probe comprises the steps of:

a) obtaining a sample of a tissue or body fluid; and

b) detecting the amount of messenger RNA transcribed from a gene as claimed in claims 1 to 3 in that sample in comparison to a reference sample by means of the probe.

24. Nucleotide sequence as claimed in claim 23, wherein the sample is a liver biopsy, plasma or serum.

25. Nucleotide sequence as claimed in claim 18, 20 or 21 for use as a probe for screening a liver cDNA or genomic library.

26. Nucleotide vector comprising the nucleotide sequence as claimed in claims 18 to 25.

27. Expression vector comprising the nucleotide sequence as claimed in claims 18 to 25 in operative association with a regulatory element that controls expression of the nucleotide sequence in a host cell.

28. Host cell comprising the nucleotide sequence as claimed in claim 18-25.

29. Host cell comprising the nucleotide sequence as claimed in claim 18-25 in operative association with a regulatory element that controls expression of the nucleotide sequence in that host cell.

30. Transgenic animal in which the gene as claimed in claim 1 or 2 is expressed transgene comprised in the genome of the animal.

31. Transgenic animal in which expression of the gene as claimed in claim 1 or 2 is prevented or repressed.

32. Method for treating liver disorder, comprising administering a compound that modulates the expression of the gene as claimed in claim 1 or 2, or the activity of the gene product of that gene to a patient in need of such treatment.

33. Method as claimed in claim 32 wherein the compound is an antisense or ribozyme molecule that blocks translation of the target gene.

34. Method as claimed in claim 32 wherein the compound is complementary to the 5' region of the target gene and blocks transcription via triple helix formation.

35. Method as claimed in claim 32 wherein the compound is an antibody that neutralizes the activity of the target gene product.

36. Method as claimed in claim 32 wherein the compound enhances the expression of the target gene, or the synthesis or activity of the gene product.

37. Method for treating liver disorder comprising administering nucleic acid encoding the gene as claimed in claim 1 or 2 to a patient in need of such treatment.

38. Method for treating liver disorder comprising administering an effective amount of the gene product of the gene as claimed in claim 1 or 2 to a patient in need of such treatment.

39. Method for enhancing the growth or regeneration of liver tissue comprising treating the liver tissue with an effective amount of the gene product of the gene as claimed in claim 1 or 2.

40. Method as claimed in claim 39 wherein the liver tissue is extracorporeal.

41. Method as claimed in claim 39 wherein the liver tissue is intracorporeal.

1/17

1 GCATCGTGGA AAGCATGGCT GCCGTCAATCA CCTGGGCACT CGCCCTCCTC
51 TCAGTGTTTG CAACTGTACA GGCAGGAAG AGCTTCTGGG AGTACTTCGG
101 CCAGAACAGC CAGGGCAAAG GCATGATGGG CCAGCAGCAG AAGCTGGCAC
151 AGGAGAGCCT GAAAGGTAGC TTGGAGCAAG ACCTCTACAA TATGAACAAT
201 TTCCTAGAAA AGCTGGGACC CTTGAGAGAG CCTGGGAAGG AGCCTCCTCG
251 GCTGGCACAG GATCCAGAAG GCATTCGGAA GCAGTTGCAG CAAGAGCTGG
301 AGGAAGTGAG CACACGCCCTG GAGCCCTACA TGGCTGCAAA GCACCAGCAG
351 GTCGGCTGGA ACCTGGAGGG CTTGAGGCAG CAGTTGAAAC CCTACACGGT
401 CGAGCTGATG GAGCAGGTAG GCCTGAGCGT GCAGGATCTG CAAGAACAGC
451 TGCGCATGGT GGGAAAAGGC ACCAAGGCC AGCTCCTGGG GGGCGTGGAT
501 GAGGCGATGA GCCTGCTGCA GGATATGCAA AGTCGAGTGC TGCACCATAC
551 GGACCGAGTC AAAGAACTCT TCCACCCCTTA TGCAGAACGC TTGGTGACTG
601 GAATTGGGCA CCATGTGCAG GAGCTGCACC GGAGTGTTC TCCTCACGCA
651 GTTGCCAGCC CCGCGAGACT CAGTCGCTGC GTGCAGACCC TGTCCCACAA
701 ACTCACACGT AAGGCGAAGG ACTTGCACAC CAGCATCCAA CGCAACCTGG
751 ATCAGCTGCG AGATGAGCTC AGTACCTTCA TCCGTGTCAG CACAGACGGG
801 GCAGACAACA GAGACTCCCT GGACCCCTCAA GCTCTCTCTG ACGAGGTCCG

FIG. 1A-1

2/17

851 CCAGAGACTC CAGGCTTTC GACATGACAC CTACCTGCAG ATCGCTGCAT
901 TCACTCAGGC CATTGACCAG GAGACCGAGG AAATCCAGCA CCAGCTGGCA
951 CCACCCCCGC CTAGCCACAG CGCCTTCGCT CCAGAGTTGG GACACTCAGA
1001 CAGTAATAAG GCCCTGAGCA GACTGCAGAG CCGGCTGGAC GACCTCTGGG
1051 AAGATATTGC CTATGGCCTT CATGACCAGG GCCATAGTCA GAATAACCCCT
1101 GAGGTCACT CAGGTTAACT CTGCAGCTCG TTGTCTGGAC CCTGAGCCCTT
1151 CAGCATGGCC TAATAGGCAG AGGGTGGAGG GTCCCTGCATA CTATTGGCGA
1201 GGCCACCAAA GGTGCTGCTG CCCCAACCTG TCTGGCCTCC TCAACTCCCC
1251 CACTCAGGTG CATTACACTC AGTAGGTTTG GC

FIG. 1A-2

3/7

1 GCATCGTGGA AAGCATGGCT GCCGTCAATCA CCTGGGCACT CGCCCTCCTC
51 TCAGTGTTTG CAACTGTACA GCGAGGAAG AGCTTCTGGG AGTACTTCGG
101 CCAGAACAGC CAGGGCAAAG GCATGATGGG CCAGCAGCAG AAGCTGGCAC
151 AGGAGAGCCT GAAAGGTAGC TTGGAGCAAG ACCTCTACAA TATGAACAAT
201 TTCCTAGAAA AGCTGGGACC CTTGAGAGAG CCTGGGAAGG AGCCTCCTCG
251 GCTGGCACAG GATCCAGAAG GCATTGGA GAGTTGCAG CAAGAGCTGG
301 AGGAAGTGAG CACACGCCCTG GAGCCCTACA TGGCTGCAAA GCACCAGCAG
351 GTCGGCTGGA ACCTGGAGGG CTTGAGGCAG CAGTTGAAAC CCTACACGGT
401 CGAGCTGATG GAGCAGGTAG GCCTGAGCGT GCAGGATCTG CAAGAACAGC
451 TGCGCATGGT GGAATAAGGC ACCAAGGCC AGCTCCTGGG GGGCGTGGAT
501 GAGGCGATGA GCCTGCTGCA GGATATGCAA AGTCGAGTGC TGCACCATAC
551 GGACCGAGTC AAAGAACTCT TCCACCCCTTA TGCAGAACGC TTGGTGACTG
601 GAATTGGGCA CCATGTGCAG GAGCTGCACC GGAGTGTGC TCCTCACGCA
651 GTTGCCAGCC CCGCGAGACT CAGTCGCTGC GTGCAGACCC TGTCCCACAA
701 ACTCACACGT AAGCGAAGG ACTTGACAC CAGCATCCAA CGCAACCTGG
751 ATCAGCTGCG AGATGAGCTC AGTACCTTCA TCCGTGTGAG CACAGACGGG
801 GCAGACAACA GAGACTCCCT GGACCCCTCAA GCTCTCTCTG ACGAGGTCCG

FIG. 1B-1

4/17

851 CCAGAGACTC CAGGCTTTTC GACATGACAC CTACCTGCAG ATCGCTGCAT
901 TCACTCAGGC CATTGACCAG GAGACCGAGG AAATCCAGCA CCAGCTGGCA
951 CCACCCCCGC CTAGCCACAG CGCCTTCGCT CCAGAGTTGG GACACTCAGA
1001 CAGTAATAAG GCCCTGAGCA GACTGCAGAG CCGGCTGGAC GACCTCTGGG
1051 AAGATATTGC CTATGGCCTT CATGACCAGG GCCATAGTCA GAATAACCCT
1101 GAGGGTCACT CAGGTTAACT CTGCAGCTCG TTGTCTGGAC CCTGAGCCTT
1151 CAGCATGGCC TAATAGGCAG AGGGTGGAGG GTCCTGCATA CTATTGGCGA
1201 GGCCACCAAA GGTGCTGCTG CCCC AACCTG TCTGGCCTCC TCAACTCCCC
1251 CACTCAGGTG CATTACACTC AGTAGGTTG GCAAACACAG CTTCCGGTGC
1301 TCATTTGGA TCCTAAGGAG CAAGAGTGGG GTGAAGGAG TGGGAGATG
1351 GTGTGCGGG GAGACTGACT GCAAGCCAGT ACTTGACCGT TGCTAGAAAC
1401 CTGTGTCACT ACAACCTGGA GCCCGGCTCC TATTACTTCA TGCCTGATGG
1451 TCGCTGTTAT AGTCGGTCTA CAGAGGGGAA CTCCTGTCTC CCCAGGGTTG
1501 TCATGACAGC CTTTGTTGGA AGAGAGCAGG AGAACATGAC ACGTATGATG
1551 GAGTGTGTAC ATCCCTGCCA GTGTCCTGC TGGGGAATC AGTGATGGGA
1601 TAAATGTGTG CATCCCTGCA GTGTCCTGC TGGGGATCA GTGATGGGAT
1651 GGGGCAGAGC CCCTATTTC TTAGAGAACT CTAACCCAAA TAAGGAACTG

FIG. 1B-2

1701 AGCCCTCTGC AGTGAGGGCT TCTGAAACC CTGTACATAG CAAACTGTGT
1751 GCCCTCTTCA TCATGCAGTC CCCACCTCCT GATTCTCGGG ATGGAACCTGA
1801 CTTTGGTTG GAATGAAATA GACGCTCATG ATGG

FIG. 1B-3

5/17

1 MAAVITWALA LLSVFATVQA RKSFWYFGQ NSQKGMMGQ QQKLAQESLK
51 GSLEQDLNMM NNFLEKLGPL REPGKEPPRL AQDPEGIRKQ LQEELEEVST
101 RLEPYMAAKH QQVGWNLEGL RQQLKPYTVE LMEQVGLSVQ DLQEQLRMVG
151 KGTKAQLLGG VDEAMSLLOD MQSRVLHHTD RVKELFHPYA ERLVTGIGHH
201 VQELHRSVAP HAVASPARLS RCVQTLSHKL TRKAKDLHTS IQRNLDQLRD
251 ELSTFIRVST DGADNRDSDL PQALSDEVRO RLQAFRHDY LQIAAFTQAI
301 DQETEEIQHQ LAPPPPSHA FAPELGHSDS NKALSRLQSR LDDLWEDIAY
351 GLHDQGHSON NPEGHSG*

FIG. 2

6/17

EPO - DG 1

27. 09. 1999

(67)

Best Available Copy

FIG. 4 A






FIG. 3

7/17

FIG. 4B




FIG. 5

9/17

1 GAGCAGATAA TGGCAAGCAT GGCTGCCGTG CTCACCTGGG CTCTGGCTCT
51 TCCTTTCAGCG TTTTCGGCCA CCCAGGCACG GAAAGGCTTC TGGGACTACT
101 TCAGCCAGAC CAGCGGGGAC AAAGCAGGG TGGAGCAGAT CCATCAGCAG
151 AAGATGGCTC GCGAGCCCGC GACCTGAAA GACAGCCTTG AGCAAGACCT
201 CAACAATATG AACAAATTCC TGGAAAAGCT GAGGCCTCTG AGTGGAGCG
251 AGGCTCCTCG GCTCCCACAG GACCCGGTGG GCATGCGGCG GCAGCTGCAG
301 GAGGAGTTGG AGGAGGTGAA GGCTCGCCTC CAGCCCTACA TGGCAGAGGC
351 GCACGAGCTG GTGGGCTGGA ATTTGGAGGG CTTGCGGCAG CAACTGAAGC
401 CCTACACGAT GGATCTGATG GAGCAGGTGG CCCTGCGCGT GCAGGAGCTG
451 CAGGAGCAGT TGC GCGTGGT GGGGAAGAC ACCAAGGCC AGTTGCTGG
501 GGGCGTGGAC GAGGCTTGG CTTTGCTGCA GGGACTGCAG AGCCGCGTGG

FIG. 6A-1

10/17

551 TGCACCACAC CGGCCGCTTC AAAGAGCTCT TCCACCCATA CGCCGAGAGC
601 CTGGTGAGCG GCATCGGGCG CCACGTGCAG GAGCTGCACC GCAGTGTGGC
651 TCCGCACGCC CCCGCCAGCC CCGCGCGCCT CAGTCGCTGC GTGCAGGTGC
701 TCTCCCGGAA GCTCACGCTC AAGCCAAGG CCTGCAAGC ACGCATCCAG
751 CAGAACCTGG ACCAGCTGCG CGAAGAGCTC AGCAGAGCCT TTGCAGGCAC
801 TGGGACTGAG GAAGGGGCG GCCCGGACCC CCAGATGCTC TCCGAGGAGG
851 TGCGCCAGCG ACTTCAGGCT TTCCGCCAGG ACACCTACCT GCAGATAGCT
901 GCCTTCACTC GCGCCATCGA CCAGGAGACT GAGGAGGTCC AGCAGCAGCT
951 GCGGCCACCT CCACCAGGCC ACAGTGCCTT CGCCCCAGAG TTTCAACAAA
1001 CAGACAGTGG CAAGGTTCTG AGCAAGCTGC AGGCCCGTCT GGATGACCTG
1051 TGGGAAGACA TCACTCACAG CCTTCATGAC CAGGGCCACA GCCATCTGGG

FIG. 6A-2

1101 GGACCCCTGA GGATCTACCT GCCCAGGCC ATTCCAGCT CCTTGTCTGG
1151 GGAGCCCTTG CTCTGAGCCT CTAGCATGGT TCAGTCCCTG AAAGTGGCCT
1201 GTTGGGTGGA GGGTGAAGG TCCTGTGCAG GACAGGGAGG CCACCAAAGG
1251 GGCTGCTGTC TCCTGCATAT CCAGCCTCCT GCGACTCCCC AATCTGGATG
1301 CATTACATTC ACCAGGCTTT GC

FIG. 6A-3


12/17

1 GAGCAGATAA TGGCAAGCAT GGCTGCCGTG CTCACCTGGG CTCTGGCTCT
51 TCTTTCAGCG TTTTCGGCCA CCCAGGCACG GAAAGGCTTC TGGGACTACT
101 TCAGCCAGAC CAGCGGGGAC AAAGCAGGG TGGAGCAGAT CCATCAGCAG
151 AAGATGGCTC GCGAGCCCGC GACCCTGAAA GACAGCCTTG AGCAAGACCT
201 CAACAATATG AACAAATTCC TGGAAAAGCT GAGGCCCTCTG AGTGGGAGCG
251 AGGCTCCTCG GCTCCACACAG GACCCGGTGG GCATGCGGCG GCAGCTGCAG
301 GAGGAGTTGG AGGAGGTGAA GGCTCGCCTC CAGCCCTACA TGGCAGAGGC
351 GCACGAGCTG GTGGGCTGGA ATTTGGAGGG CTTGCGGCAG CAACTGAAGC
401 CCTACACGAT GGATCTGATG GAGCAGGTGG CCCTGCGCGT GCAGGAGCTG
451 CAGGAGCAGT TCGCGGTGGT GGGGGAAGAC ACCAAGGCC AGTTGCTGGG
501 GGGCGTGGAC GAGGCTTGG CTTTGCTGCA GGGACTGCAG AGCCGCGTGG

FIG. 6B-1

13/17

551 TGCACCACAC CGGCCGCTTC AAAGAGCTCT TCCACCCATA CGCCGAGAGC
601 CTGGTGAGCG GCATCGGGCG CCACGTGCAG GAGCTGCACC GCAGTGTGGC
651 TCCGCACGCC CCCGCCAGCC CCGCGCGCCT CAGTCGCTGC GTGCAGGTGC
701 TCTCCCGGAA GCTCAGCTC AAGGCCAAGG CCTGCAACG ACGCATCCAG
751 CAGAACCTGG ACCAGCTGCG CGAAGAGCTC AGCAGAGCCT TTGCAGGCAC
801 TGGGACTGAG GAAGGGGCGG GCCCGGACCC CCAGATGCTC TCCGAGGAGG
851 TCGGCCAGCG ACTTCAGGCT TTCCGCCAGG ACACCTACCT GCAGATAGCT
901 GCCTTCACTC GCGCCATCGA CCAGGAGACT GAGGAGGTCC AGCAGCAGCT
951 GCGGCCACCT CCACCAGGCC ACAGTGCCTT CGCCCCAGAG TTTCAACAAA
1001 CAGACAGTGG CAAGGTTCTG AGCAAGCTGC AGGCCCGTCT GGATGACCTG
1051 TGGGAAGACA TCACTCACAG CCTTCATGAC CAGGGCCACA GCCATCTGGG


FIG. 6B-2

1101 GGACCCCTGA GGATCTACCT GCCCAGGCC CATTCCAGCT CCTTGTCTGG
1151 GGAGCCTTGG CTCGTAGCCT CTAGCATGGT TCAGTCCTTG AAAGTGGCCT
1201 GTTGGGTGGA GGGTGAAGG TCCTGTGCAG GACAGGAGG CCACCAAAGG
1251 GGCTGCTGTC TCCTGCATAT CCAGCCTCCT GCGACTCCCC AATCTGGATG
1301 CATTACATTC ACCAGGCTTT GCAAACCCAG CCTCCCAGTG CTCATTGGG
1351 AATGCTCATG AGTTACTCCA TTCAAGGGTG AGGGAGTAGG GAGGGAGAGG
1401 CACCATGCAT GTGGGTGATT ATCTGCAAGC CTGTTTGCCG TGATGCTGGA
1451 AGCCTGTGCC ACTACATCCT GGAGTTTGGC TCTAGTCACT TCTGGCTGCC
1501 TGGTGGCCAC TGCTACAGCT GGTCCACAGA GAGGAGCACT TGTCTCCCA
1551 GGGCTGCCAT GGCAGCTATC AGGGAATAG AAGGGAGAAA GAGAATATCA
1601 TGGGGAGAAC ATGTGATGGT GTGTGAATAT CCCTGCTGGC TCTGATGCTG

14/17

FIG. 6B-3

15/17

1651 GTGGGTACGA AAGGTGTGGG CTGTGATAGG AGAGGGCAGA GCCCATGTTT
1701 CCTGACATAG CTCTACACCT AAATAAGGA CTGAACCCCTC CCAACTGTGG
1751 GAGCTCCTTA AACCTCTGG GGAGCATACT GTGTGCTCTC CCCATCTCCA
1801 GCCCCCTCCCT CTGGGTCCC AAGTTGAAGC CTAGACTTCT GGCTCAAATG
1851 AAATAGATGT TTATGAT


FIG. 6B-4

1 MAAVLTWALA LLSAFSATQA RKGFDYFSQ TSGDKGRVEQ IHQQMAREP
51 ATLKDSLEQD LNNMKNFLEK LRPLSGSEAP RLPQDPVGMR RQLQEELEEV
101 KARLPYMAE AHELVGNLE GLRQQLKPYT MDLMEQVALR VQELQEQLRV
151 VGEDTKAQLL GGVDEAWALL QGLQSRVVHH TGRFKELFHP YAESLVSGIG
201 RHVQELHRSV APHAPASPAR LSRCVQVLSR KLTLKAKALH ARIQQNLDQL
251 REELSRAFAG TGTEEGAGPD PQMLSEEVRO RLQAFRQDTY LQIAAFTRAI
301 DQETEEVQQQ LAPPPGHSFAPEFQQTDS GKVLSKLQAR LDDLWEDITH
351 SLHDQGHSHL GDP*

16/17

FIG. 7

17/17



Best Available Copy

FIG. 8

3h 6h pos. 12h
hpx sham hpx sham contr. hpx sham




FIG. 9





INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 15/12, C07K 14/47, 16/18, C12Q 1/68, A01K 67/027	A3	(11) International Publication Number: WO 00/03013 (43) International Publication Date: 20 January 2000 (20.01.00)
(21) International Application Number: PCT/EP99/04938 (22) International Filing Date: 12 July 1999 (12.07.99) (30) Priority Data: 98202336.8 10 July 1998 (10.07.98) EP (71) Applicant (for all designated States except US): AMS- TERDAM MOLECULAR THERAPEUTICS [NL/NL]; Bernadottelaan 15, NL-3527 GA Utrecht (NL). (72) Inventors; and (75) Inventors/Applicants (for US only): CHAMULEAU, Robert, Antoine, François, Marie [NL/NL]; Van Ostadelaan 76, NL-1412 JL Naarden (NL). GROENINK, Martijn [NL/NL]; Torasistraat 5, NL-1019 RT Amsterdam (NL). VAN DER VLIET, Hendrik, Niels [NL/NL]; Bovenweg 18, NL-1276 XZ Huizen (NL). LEEGWATER, Adam, Cornelis, Jozef [NL/NL]; t Modderweidje 9, NL-1738 CR Waarland (NL). (74) Agent: VAN SOMEREN, Petronella, Francisca, Hendrika, Maria; Arnold & Siedsma, Sweelinckplein 1, NL-2517 GK The Hague (NL).	(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims</i> <i>and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 24 February 2000 (24.02.00)	

(54) Title: GENE AND PROTEIN INVOLVED IN LIVER REGENERATION**(57) Abstract**

The present invention relates to a gene involved in regeneration processes of the liver and comprising a nucleotide sequence which is at least 70 % homologous to the sequence of figure 1 or the sequence of figure 6, or the complementary strand thereof, for use in the design of PCR probes for detecting nucleotide sequences in a source material, which nucleotide sequences represent genes corresponding with the gene sequence of figure 1 or the sequence of figure 6; protein encoded by said gene for use in diagnosis of liver regeneration and/or liver cell proliferation; and antibodies directed against this protein, a PCR primer comprising at least part of said gene as a probe, a single stranded nucleotide sequence being at least in part complementary to the messenger RNA transcribed from said gene as a probe an expression vector and a host cell comprising said nucleotide sequence, for use in a method for detecting the occurrence of liver cell proliferation in a subject.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/04938

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C07K14/47 C07K16/18 C12Q1/68 A01K67/027

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K C12N C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MARRA M ET AL.: "Sugano mouse liver mlia Mus musculus cDNA clone 1431407 similar to apolipoprotein A-IV (accession number AA987093)" EMBL SEQUENCE DATABASE, 29 May 1998 (1998-05-29), XP002095461 Heidelberg, Germany the whole document ---	3, 12-14, 16-25
A	WO 96 39540 A (ADVANCED TISSUE SCIENCES INC) 12 December 1996 (1996-12-12) the whole document --- -/--	1-41

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

20 December 1999

Date of mailing of the international search report

14/01/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Oderwald, H

INTERNATIONAL SEARCH REPORT

Int. Application No

PCT/EP 99/04938

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	<p> DATABASE R60U083 'Online! EMBL, Heidelberg, Germany AC/ID AC007707, 3 June 1999 (1999-06-03) HU P AND ROE B A: "Homo sapiens chromosome 11 clone 442e11 from RPC111" XP002125969 see nucleotides 75500 to 76800 abstract ----- </p>	<p> 1-4, 12-14, 16-29 </p>

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 99/04938

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 32-41
are directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims: it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Inter. Application No

PCT/EP 99/04938

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9639540 A	12-12-1996	AU 6160396 A	24-12-1996
		CA 2223707 A	12-12-1996
		EP 0832289 A	01-04-1998
		JP 11507816 T	13-07-1999
		NZ 310749 A	28-10-1999
